Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients With Moderate to Severe Rheumatoid Arthritis

NCT06596772 is registered in ClinicalTrials.gov with mAbxience Research S.L. as lead sponsor.

NCT NCT06596772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
mAbxience Research S.L.
Phase
Phase 3
Overall status
Completed
Start date
October 3, 2024
Completion date
February 20, 2026
Enrollment
501 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)